Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib mesylate tablets combined with chemotherapy as second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR-OPC-17010572Phase 4Not yet recruiting
- Sponsor
- Yangzhong People's Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Yangzhong People's Hospital. Primary endpoint: Overall survival. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR-OPC-17010572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17010572.